Results 131 to 140 of about 6,890,863 (253)
Autism Research, EarlyView.ABSTRACT Autism spectrum disorder (ASD) is frequently associated with motor difficulties that may affect daily functioning, participation in physical activity, and developmental outcomes. Although motor impairments have been widely reported in this population, comparative evidence against typically developing (TD) peers remains fragmented across ...
Nerea Blanco‐Martínez +4 more
wiley +1 more source
Quality of Life in Autism: A Systematic Review and Meta‐Analysis of Patients and Caregivers
Autism Research, EarlyView.ABSTRACT Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition associated with significant challenges in daily functioning and well‐being. Caregivers often experience substantial psychological and physical burden. However, comprehensive synthesis of quality of life (QoL) outcomes for both individuals with ASD and their caregivers ...
Kamila Castro +11 more
wiley +1 more source
The economic theory and the Portuguese manufactured industry [PDF]
This work aims to test the Verdoorn Law, with the alternative specifications of (1)Kaldor (1966), for the five Portuguese regions (NUTS II), from 1986 to 1994. It is intended to test, yet in this work, the alternative interpretation of (2)Rowthorn (1975)
Martinho, Vítor João Pereira Domingues
core
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source
Regulatory harmonization: Evolution, globalization and future directions
British Journal of Clinical Pharmacology, EarlyView.Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm +2 more
wiley +1 more source
Implementation and use of risk minimization control tools in the EU: A multistakeholder survey
British Journal of Clinical Pharmacology, EarlyView.Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink +21 more
wiley +1 more source